Addiction Medicine
Cytos Biotechnology enters exclusive license agreement with Novartis to develop, manufacture and commercialize novel vaccine for treatment of nicotine addiction
Published in Lab Law Weekly, May 18th, 2007
Under the terms of the agreement, Novartis is granted world-wide exclusive rights for CYT002-NicQb and is responsible for late stage clinical development, manufacturing, and commercialization of the vaccine. In return, Cytos Biotechnology is eligible to receive up to CHF 600 million in upfront and potential development, regulatory approval and sales milestone payments based...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2007-05-18)
More Articles from Lab Law Weekly
- AARP
AARP Launches Statewide Campaign for Health Care Reform - AARP Illinois
AARP Illinois Joins Governor in Fight for Health Care Reform - Advanced Medical Solutions Group
Proposal for the reduction of the Company's share capital by the cancellation of its Deferred Shares of 5p each and the cancellation of its share premium account - Aging
Women Assuming Primary Caregiving Role as Society Ages - Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals Announces Exercise of Over-Allotment Option - Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
